Pregnancy outcome following exposure to topical retinoids: A multicenter prospective study

Journal of Clinical Pharmacology

Volumn 52, Issue 12, 2012, Pages 1844-1851

  Panchaud, Alice ^a   Csajka, Chantal ^b   Merlob, Paul ^c   Schaefer, Christof ^d   Berlin, Maya ^e   De Santis, Marco ^f   Vial, Thierry ^g   Ieri, Alessandra ^h   Malm, Heli ⁱ   Eleftheriou, Georgios ^j   Stahl, Bracha ^c   Rousso, Philippe ^a   Winterfeld, Ursula ^a   Rothuizen, Laura E ^a   Buclin, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c RABIN MEDICAL CENTER   (Israel)

^d Pharmakovigilanz und Beratungszentrum Embryonaltoxikologie   (Germany)

^e Drug Consultation TIS   (Israel)

^f Telefono Rosso TIS   (Italy)

^g Pharmacovigilance   (France)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j Poison Control Centre   (Italy)

more..

Author keywords

birth defect; Clinical pharmacology; drug information; pregnancy; topical retinoid

Indexed keywords

ADAPALENE; ISOTRETINOIN; MOTRETINIDE; RETINOIC ACID; RETINOID;

ADULT; ANGIOMA; ANKYLOGLOSSIA; AORTA COARCTATION; ARTICLE; BIRTH DEFECT; BLURRED VISION; CLEFT PALATE; CONGENITAL CATARACT; CONGENITAL NEVUS; CONTROLLED STUDY; CRYPTORCHISM; EMBRYOPATHY; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; HALLUX VARUS; HEART VENTRICLE SEPTUM DEFECT; HEMANGIOMA; HUMAN; HYPERMETROPIA; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MICROPHTHALMIA; MULTICENTER STUDY; NEWBORN; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; PULMONARY VALVE STENOSIS; RISK BENEFIT ANALYSIS; SPONTANEOUS ABORTION;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; FEMALE; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RETINOIDS; SKIN DISEASES; YOUNG ADULT;

EID: 84862679725     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011429566     Document Type: Article

References (31)

1. Lammer EJ, Schunior A, Hayes AM, et al. Isotretinoin dose and teratogenicity. Lancet. 1988 ; 2 (8609). 503-504
2. Adams J, Lammer EJ. Neurobehavioral teratology of isotretinoin. Reprod Toxicol. 1993 ; 7 (2). 175-177
3. US Food and Drug Administration. iPLEDGE. http://www.fda.gov/Drugs/ DrugSafety/Postmarket DrugSafety Informationfor PatientsandProviders/ucm094305. htm. Accessed July 14, 2011.
4. De Santis M, Straface G, Cavaliere A, et al. The need for restricted prescription of retinoic acid derivative isotretinoin to prevent retinoid teratogenicity. Prev Med. 2007 ; 45 (2-3). 243-244
5. Clewell HJ, Andersen ME, Wills RJ, et al. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol. 1997 ; 36 (3, pt 2). S77 - S85
6. Jensen BK, McGann LA, Kachevsky V, et al. The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol. 1991 ; 24 (3). 425-428
7. Latriano L, Tzimas G, Wong F, et al. The percutaneous absorption of topically applied tretinoin and its effect on end-ogenous concentrations of tretinoin and its metabolites after single doses or long-term use. J Am Acad Dermatol. 1997 ; 36: S37 - S46
8. Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet. 1999 ; 37 (4). 273-287
9. Van Hoogdalem EJ, Baven TL, Spiegel-Melsen I, et al. Transdermal absorption of clindamycin and tretinoin from topically applied anti-acne formulations in man. Biopharm Drug Dispos. 1998 ; 19 (9). 563-569
10. Willhite CC, Sharma RP, Allen PV, et al. Percutaneous retinoid absorption and embryotoxicity. J Invest Dermatol. 1990 ; 95 (5). 523-529
11. Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream. Lancet. 1992 ; 339 (8794). 687
12. Colley SM, Walpole I, Fabian VA, et al. Topical tretinoin and fetal malformations. Med J Aust. 1998 ; 168 (9). 467
13. Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993 ; 341 (8856). 1352-1353
14. Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, et al. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother. 1998 ; 32 (4). 505-506
15. Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000 ; 22 (4). 218-220
16. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993 ; 341 (8854). 1181-1182
17. Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005 ; 136 (2). 117-121
18. Shapiro L, Pastuszak A, Curto G, et al. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet. 1997 ; 350 (9085). 1143-1144
19. Autret E, Berjot M, Jonville-Bera AP, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet. 1997 ; 350 (9074). 339
20. Carlier P, Choulika S, Dally S. Topical retinoids exposure in pregnancy. Thérapie. 1998 ; 53: 180
21. Martinez-Frias ML, Rodriguez-Pinilla E. First-trimester exposure to topical tretinoin: its safety is not warranted. Teratology. 1999 ; 60 (1). 5
22. Bozzo P, Chua-Gocheco A, Einarson A. Safety of skin care products during pregnancy. Can Fam Physician. 2011 ; 57 (6). 665-667
23. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy: 15 years experience of ENTIS. Reprod Toxicol. 2005 ; 20 (3). 331-343
24. Clementi M, Di Gianantonio E, Ornoy A. Teratology information services in Europe and their contribution to the prevention of congenital anomalies. Community Genet. 2002 ; 5 (1). 8-12
25. Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol. 2003 ; 67 (3). 193-201
26. Buchan P, Eckhoff C, Caron D, et al. Repeated topical administration of all-trans-retinoic acid and plasma levels of retinoic acids in humans. J Am Acad Dermatol. 1994 ; 30 (3). 428-434
27. Chen C, Jensen BK, Mistry G, et al. Negligible systemic absorption of topical isotretinoin cream: implications for teratogenicity. J Clin Pharmacol. 1997 ; 37 (4). 279-284
28. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. J Am Acad Dermatol. 1996 ; 34 (3). 482-485
29. Koren G, Bologa M, Long D, et al. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol. 1989 ; 160 (5, pt 1). 1190-1194
30. Nordeng H, Ystrom E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol. 2010 ; 66 (2). 207-214
31. Croen LA, Shaw GM. Young maternal age and congenital malformations: a population-based study. Am J Public Health. 1995 ; 85 (5). 710-713